GlassScriptPhysician profile
James A Moghtader
NPI 1568475424
$36,972.27
in general payments reported to CMS, 2019-2025
23 companies · $1,849 in 2025
The $1,849 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,759 · 2020: $6,237 · 2021: $3,399 · 2022: $5,613 · 2023: $5,404 · 2024: $5,711 · 2025: $1,849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,650 · Food and Beverage: $2,771 · Travel and Lodging: $405 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,650.00 |
| Food and Beverage | $2,770.62 |
| Travel and Lodging | $404.62 |
| Education | $138.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $17,778.24 | 2021-2025 | |
| Allergan, INC. | $8,983.68 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $5,832.42 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $750.01 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $422.61 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $328.45 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $322.67 | 2019-2025 | Rexulti |
| Lundbeck LLC | $311.77 | 2019-2025 | Rexulti, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $310.84 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $279.21 | 2021-2025 | Austedo Xr |
| Alkermes, INC. | $226.75 | 2021-2025 | Aristada, Lybalvi |
| Bausch Health US, LLC | $202.59 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $194.04 | 2019-2025 | Invega Sustenna, Spravato |
| Axsome Therapeutics, INC. | $190.93 | 2023-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $184.31 | 2019-2025 | Fanapt |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainsway USA INC | $135.97 | 2025 | Deep Tms System |
| Ironshore Pharmaceuticals INC. | $115.77 | 2019 | |
| Almatica Pharma LLC | $113.14 | 2024-2025 | Loreev Xr |
| Merck Sharp & Dohme LLC | $104.38 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $94.97 | 2022-2025 | Nuplazid |
| Jazz Pharmaceuticals INC. | $34.89 | 2021-2022 | |
| Shire North American Group INC | $33.53 | 2019 | |
| Sun Pharmaceutical Industries INC. | $21.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Moghtader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.